STELARA

Reason for request

Clinical Benefit

Insufficient	The actual benefit for other patients who do not meet these criteria for receiving this treatment is insufficient.
Substantial	The opinion’s Committee is of the actual benefit provided by STELARA 45 mg solution for injection is substantial in adult patients suffering from serious chronic plaque psoriasis who have failed at least two systemic treatments, including phototherapy, methotrexate and ciclosporin (i.e. have not responded or cannot receive these treatments because of contraindication or intolerance).

Clinical Added Value

minor

STELARA 45 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy compared to ENBREL among patients suffering from serious chronic plaque psoriasis who have failed at least two systemic treatments from among phototherapy, methotrexate and ciclosporin.